Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Le résumé fourni par la source
Figure S8: Acquired resistance to the combination of LB-100 and adavosertib suppressed malignant traits in CRC models (A) IncuCyte-based proliferation assays from HT-29 and SW-480 parental and resistant cells in the absence or presence of the combination (LB-100 4 µM + adavosertib 400 nM). (B) Chromosome counting and representative chromosome spreads from HT-29 and SW-480 parental and resistant cells. Nocodazole was added for 3h to block cells in mitosis. Cells were harvested by mitotic shake-off for spreading. Over 40 (HT-29 and HT-29-R) or 50 (SW-480 and SW-480-R) spreads were counted per cell line. Asterisks indicate significance level (**** p-value <0.0001) by two-tailed Mann-Whitney test. (C) Heatmaps showing the marker genes of each cluster from the scRNAseq analyses of HT-29 and SW-480 cells
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
- Date Crossref
- 17/06/2026
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.